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Epigenetic dysregulation of gene expression is thought to be critically involved in the pathophysiology of
Alzheimer’s disease (AD). Recent studies indicate that DNA methylation and DNA hydroxymethylation
are 2 important epigenetic mechanisms that regulate gene expression in the aging brain. However, very
little is known about the levels of markers of DNA methylation and hydroxymethylation in the brains of
patients with AD, the cell-type speciﬁcity of putative AD-related alterations in these markers, as well as
the link between epigenetic alterations and the gross pathology of AD. The present quantitative
immunohistochemical study investigated the levels of the 2 most important markers of DNA methylation
and hydroxymethylation, that is, 5-methylcytidine (5-mC) and 5-hydroxymethylcytidine (5-hmC), in the
hippocampus of AD patients (n ¼ 10) and compared these to non-demented, age-matched controls
(n ¼ 10). In addition, the levels of 5-hmC in the hippocampus of a pair of monozygotic twins discordant
for AD were assessed. The levels of 5-mC and 5-hmC were furthermore analyzed in a cell-type and
hippocampal subregionespeciﬁc manner, and were correlated with amyloid plaque load and neuroﬁ-
brillary tangle load. The results showed robust decreases in the hippocampal levels of 5-mC and 5-hmC
in AD patients (19.6% and 20.2%, respectively). Similar results were obtained for the twin with AD when
compared to the non-demented co-twin. Moreover, levels of 5-mC as well as the levels of 5-hmC showed
a signiﬁcant negative correlation with amyloid plaque load in the hippocampus (rp ¼ 0.539, p ¼ 0.021
for 5-mC and rp ¼ 0.558, p ¼ 0.016 for 5-hmC). These human postmortem results thus strengthen the
notion that AD is associated with alterations in DNA methylation and hydroxymethylation, and provide
a basis for further epigenetic studies identifying the exact genetic loci with aberrant epigenetic
signatures.
 2013 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
The biological mechanisms that underlie age-related dysfunc-
tion and the pathophysiology of Alzheimer’s disease (AD) are still
largely unknown. Recent ﬁndings have suggested that aging and AD
are associated with profound changes in the epigenetic regulationally to this work.
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sevier OA license.of gene expression, especially at the level of DNA methylation
(Chouliaras et al., 2010a; Mastroeni et al., 2011). DNA methylation,
1 of the fundamental epigenetic mechanisms, regulates gene
transcription and can result in long-term changes in cellular func-
tion (Jaenisch and Bird, 2003). Methylation of CpG di-nucleotides is
catalyzed by DNAmethyltransferases (Dnmts), disrupts the binding
of transcription factors and recruits proteins known as methyl-
CpGebinding domain proteins (MBDs) that are associated with
chromatin compaction and gene silencing (Cedar and Bergman,
2009). DNA hydroxymethylation is a newly described epigenetic
modiﬁcation derived from the oxidation of methylated cytosines by
ten-eleven translocation (TET) enzymes (Kriaucionis and Heintz,
2009; Tahiliani et al., 2009). Recent evidence suggested that the
Table 1
Characteristics of Alzheimer’s disease casees and non-demented controls
Characteristic Non-demented controls Alzheimer’s disease cases
Age Mean ¼ 77.91, SD¼ 4.1 Mean ¼ 75.36, SD ¼ 5.5
Sex (female/male) 3/7 W ¼ 3, M ¼ 7
Postmortem interval Mean ¼ 2.77, SD¼ 0.61 Mean ¼ 2.98, SD ¼ 0.93
Braak staging IeIII VeVI
Hippocampal amyloid
plaques
Mean ¼ 0.00, SD ¼ 0.00 Mean ¼ 2.22, SD ¼ 0.56
Hippocampal
neuroﬁbrillary tangles
Mean ¼ 0.81, SD ¼ 0.75 Mean ¼ 2.90, SD ¼ 0.20
L. Chouliaras et al. / Neurobiology of Aging 34 (2013) 2091e20992092biological role of DNA hydroxymethylation might be different from
DNAmethylation, while it is highly abundant in the brain compared
to other tissues (Jin et al., 2011; Munzel et al., 2010; Valinluck and
Sowers, 2007; Valinluck et al., 2004).
Aging is the most important risk factor for developing AD and is
associated with aberrant DNA methylation patterns. In particular,
aging has been linked with global DNA hypomethylation and
hypermethylation of CpG islands in various bran regions, including
the frontal and temporal cortex (Christensen et al., 2009;
Hernandez et al., 2011; Siegmund et al., 2007). Other recent reports
have also shown alterations in the DNA hydroxymethylation
marker 5-hydroxymethylcytidine (5-hmC) in the agingmouse brain
(Chouliaras et al., 2012; Song et al., 2011; Szulwach et al., 2011b).
Evidence from genetic and immunohistochemical studies on AD
cases further supports the notion that aberrant DNA methylation
and hydroxymethylation are involved in the pathophysiology of AD.
A genetic association study reported an increased risk of AD for
carriers of certain genetic variants in TET1 (Morgan et al., 2008).
Immunohistochemical studies showed decreased levels of the DNA
methylation marker 5-methylcytidine (5-mC) and a variety of
enzymes and proteins involved in the process of DNA methylation,
such as Dnmt1, and methyl-CpGebinding protein 2 (MeCP2), in the
entorhinal cortex of AD patients, (Mastroeni et al., 2010). Similar
ﬁndings of decreased 5-mC were observed in the frontal cortex of
a monozygotic twin pair discordant for AD (Mastroeni et al.,
2009)dthe same twin pair used in the present study. Recent
epigenetic studies furthermore indicate gene-speciﬁc alterations in
DNA methylation in the brain, peripheral lymphocytes, and trans-
genic mouse models of AD neuropathology (Bakulski et al., 2012;
Bihaqi et al., 2011; Bollati et al., 2011; Fuso et al., 2012; Wang et al.,
2008), as reviewed by Chouliaras et al. (2010a). For example,
Bakulski et al. (2012) have found disease-associated methylation
differences in 948 of 27,578 CpG sites examined using a genome-
wide DNA methylation array in DNA derived from the human
prefrontal cortex (Bakulski et al., 2012), whereas Fuso et al. (2012)
have reported a decrease in the methylation of the presenilin 1
gene (PSEN1) promoter induced by vitamin B deﬁciency in cell lines
and transgenic mouse models of AD, carrying familial mutations of
the amyloid precursor protein (APP) gene (Fuso et al., 2011).
Thus, accumulating evidence suggests a role for DNA methyla-
tion and hydroxymethylation in AD. However, it is currently
unknown whether the previously reported AD-related decrements
in DNA methylation and associated molecules in the entorhinal
cortex are also present in the hippocampus, although alterations in
DNA hydroxymethylation have not been investigated so far in AD.
Furthermore, given the fact that most investigations were carried
out on whole-tissue homogenates, it remains unclear whether the
various hippocampal subregions and hippocampal cell types show
selective vulnerability for alterations in epigenetic markers, and
whether hippocampal alterations in epigenetic markers correlate
with hippocampal amyloid plaque and/or neuroﬁbrillary tangle
load.
2. Methods
2.1. Human subjects and tissue processing
Postmortem brain materials were collected through the Banner
Sun Health Research Institute Brain and Body Donation Program
(Sun City, AZ). Blocks of ﬁxed, parafﬁn-embedded hippocampal
tissue (at the level of the lateral geniculate nucleus) from 10 AD
cases and 10 age-matched controls were obtained from the donated
brains. All tissue samples were collected under institutional review
boardeapproved protocols and informed consents permitting use
of samples for research purposes. Antemortem evaluation by board-certiﬁed neurologists and neuropsychologists and postmortem
evaluation by a board-certiﬁed neuropathologist were performed
for all cases as described previously (Beach et al., 2012). The diag-
nostic criteria followed consensus guidelines for National Institute
on Aging Alzheimer’s Disease Centers. Age, sex, and postmortem
interval were well matched between the groups (Table 1). The
hippocampal tissue was sliced axially into 1-cm thick blocks,
immersed to 4% parafolmaldehyde ﬁxative solution for 48 hours at
4 C and embedded in parafﬁn. Subsequently, the parafﬁn blocks
were cut into 6-mm thick slices on a rotary microtome (Leica, Wet-
zlar, Germany), placed on microscope slides (VWR, Batavia, IL) and
stored in a dark container at room temperature until further use.
The tissue from the monozygotic twin pair was obtained from
the Boston University Alzheimer’s Disease Center. Written
informed consent for autopsy was obtained for both cases in
compliance with institutional guidelines of Boston University.
Details regarding thismonozygotic twin pair discordant for AD have
been described previously (Mastroeni et al., 2009). In brief, ante-
mortem and postmortem evaluations were performed by board-
certiﬁed neurologists and a neuropathologist who determined the
diagnosis according to the standard NIH AD centers protocols. The
AD twin died at 76 years of age, and the non-demented control (ND)
twin at 79 years of age. Postmortem delay was 7.3 hours for the AD
twin and 3.1 for the ND twin. They were autopsied at the same
facility using the same tissue processing protocols. Because of
limitations in hippocampal tissue availability, only sections con-
taining the CA1 region were available (protocols described below).
In brief, the sections were sliced axially into 1-cm thick slabs,
immersion ﬁxed for 48 hours in 4% parafolmaldehyde at 4 C,
washed in phosphate buffer (PB), and cryoprotected in ethylene
glycol and glycerol. The slabs were then sectioned at 40 mm on
a cryostat. Free-ﬂoating sections were stored in freezing solution
(glycol/glycerol/PB) at 20 C until further use (Mastroeni et al.,
2009).2.2. Immunohistochemistry and image analysis
For each marker, the sections were immunoreacted simulta-
neously using standard immunohistochemical procedures. In case
of parafﬁn-embedded sections, deparafﬁnation in 2 series of xylene,
and rehydration in series of 100%, 96%, and 80% ethanol, and
distilled water was performed before the immunohistochemical
procedure. Brieﬂy, the sections were further rinsed in phospate-
buffered saline Tween-20 (PBS-T), followed by antigen retrieval
using 10 mmol/L citrate buffer at 95 C for 20 minutes, after which
the sections were rinsed againwith PBS-T and incubated in 1% H2O2
for 30minutes to quench endogenous peroxidase. Subsequently, the
sections were rinsed in PBS-T blocked in 3% bovine serum albumin
and incubated with the primary antibodies (5-mC, diluted 1:1000,
Genway Biotech, SanDiego CA; 5-hmC, diluted 1:5000, ActiveMotif,
Carlsbad, CA) overnight at room temperature. After primary anti-
body incubation the sections were washed again and incubated for
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5-mC and goat anti-rabbit alexa 488 for 5-hmC, 1:5000; Invitrogen,
Grand Island, NY). After washing in PBS-T, the sections were coun-
terstained with Neurotrace red ﬂuorescent stain (Invitrogen),
washed again in PBS-T, taken through Sudan Black B (Sigma Aldrich,
St Louis, MO) to reduce autoﬂuorescence, air dried overnight, and
coverslipped using Vectashield mounting medium (Vector Labs,
Burlingame, CA). The Neurotrace counterstain was performed so as
to use neuron-speciﬁc analyses based on the characteristic
morphology and size of neuronal cells when stained with this
counterstain. The speciﬁcity of the 5-mC and 5-hmC primary anti-
bodies was conﬁrmed by using methylated or hydroxymethylated
nucleotides (10 nmol/L 5-mC dCTP, 10 nmol/L 5-hmC dCTP;
Zymoresearch, Irvine, CA), which brought IR levels to background
signal when pre-incubated with the primary antibodies (data not
shown).
An Olympus IX51 microscope (Olympus, Tokyo, Japan) was used
for all imaging procedures. Images were taken with the 40
objective using a green ﬂuorescence ﬁlter for each staining,
whereas their corresponding Neurotrace-counterstained images
were taken using a red ﬂuorescence ﬁlter. All images were taken
using identical camera, microscope lens, and light settings. One
hippocampal section was used per each staining, where images
were taken from 5 sites in the DG, 5 sites in the CA3, and 5 sites in
the CA1 per subject (total of 15 images per subject for each staining
concomitant with 15 corresponding Neutrorace-counterstained
images).
Fluorescence intensity analysis was performed using ImageJ
software (ImageJ, U.S. National Institutes of Health, Bethesda, MD;
imagej.nih.gov/ij/). The intensity measurements were corrected for
background differences by dividing the measured intensities with
the average intensity of a cell-free region, such as the hippocampal
white matter, in each section. For each image, the ﬂuorescence
intensity of 15 individual neurons and 15 individual cells of
non-neuronal origin were analyzed by delineating the nucleus of
each cell and measuring the mean intensity value. Thus, the ﬂuo-
rescence intensity of a total of 450 cells per individual was analyzed
per staining. The discrimination between cells of neuronal and non-
neuronal origin was done based on their characteristic morphology
and size of neurons when using the Neurotrace counterstain
(Sekirnjak et al., 2003). According to these criteria, a clear differ-
entiation between neurons and glia in the DG was not possible, and
thus no cell-type speciﬁc analyses were carried on in this subregion.
Of note, the measurements of ﬂuorescence intensities were calcu-
lated in arbitrary units and do not represent absolute levels of these
markers (Fig. 1).Fig. 1. Hippocampal 5-methylcytidine (5-mC) immunoreactivity (IR) and Neurotrace coun
Neurotrace image (red) taken from the CA1 hippocampal subregion. Based on the Neurotr
photomicrograph, and their ﬂuorescence intensity was analyzed using ImageJ software (d
whereas glial cells are highlighted with a dotted red circle. A total of 15 images per subject f
were analyzed. Scale bar ¼ 50 mm.2.3. Statistical analysis
A multilevel linear mixed model was used for the statistical
analyses. For each marker, the ﬂuorescence intensities were used as
the dependent variable and the AD diagnosis as the independent
variable. Measurements of individual cells (level 1) were clustered
in the different subjects (level 2). Statistical signiﬁcance was set at
a ¼ 0.05. Following the multilevel analyses, stratiﬁed analyses for
neuronal cells and cells of non-neuronal origin (glial cells) were
performed for each hippocampal subregion (CA3, CA1-2) or just for
neuronal cells (DG) separately using the same statistical model.
Correlation analyses were carried out by calculating the Pearson’s
correlation coefﬁcient (rp). All statistical calculations were per-
formed using STATA 11 (StataCorp, College Station, TX) or the
Statistical Package for the Social Sciences (SPSS 17; SPSS Inc, Chi-
cago, IL). Graphs were built in GraphPad Prism (Version 4, GraphPad
Software, San Diego, CA).3. Results
3.1. Qualitative analysis and quantitative analyses of 5-mC and
5-hmC IR in the hippocampus
Both 5-mC and 5-hmC IR were detected in all cells, and were
primarily observed as punctate IR in the nucleus. Microscopic
inspection suggested a striking decrease in IR of bothmarkers in the
AD hippocampus when compared to controls (Figs. 2 and 3), and
a similar pattern was observed for 5-hmC IR in the hippocampus of
the AD twinwhen compared to the ND co-twin. Quantitative image
analyses were further carried out to conﬁrm these ﬁndings.
Multilevel linear model analysis revealed a decrease of 5-mC IR in
the hippocampus of AD patients when compared to ND controls
(19.6%, p ¼ 0.006). Similarly a signiﬁcant decrease of 5-hmC IR
(20.2%, p ¼ 0.012) was observed in the AD hippocampus when
compared to ND controls (Fig. 4).3.2. 5-mC and 5-hmC in glial cells and neurons of the hippocampal
subregions
Analyses of 5-mC IR in neurons and glial cells in the 3 hippo-
campal subregions revealed that AD patients had a signiﬁcantly
decreased level of 5-mC in glial cells in the CA3 (26.9%, p ¼ 0.016),
neurons in the CA1 (21.1%, p ¼ 0.01), and glial cells in the CA1
(25.7%, p ¼ 0.003), but there were no statistically signiﬁcant
differences for the DG or the CA3 neurons (Fig. 5).terstain. Representative photomicrograph of 5-mC IR (green) and the corresponding
ace morphology, a total of 15 neurons and 15 glial cells were delineated within each
etails in text). Representative neurons are highlighted with a continuous white circle,
or each staining concomitant with 15 corresponding Neutrorace-counterstained images
Fig. 2. Representative photomicrographs of 5-mC immunoreactivity (IR). High magniﬁcation representative photomicrographs of the hippocampal DG, CA3, and CA1-2 regions.
(AeC) Non-demented control cases (ND) and (DeF) Alzheimer’s disease cases (AD). Note: A loss of 5-mC IR is observed in AD cases when compared to ND controls in all 3
hippocampal subregions. Images were taken with a 40 objective. Scale bar ¼ 50 mm.
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campal subregions revealed that AD patients had a signiﬁcantly
decreased level of 5-hmC in cells of the DG (16.1%, p ¼ 0.042) and
glial cells in the CA3 (34.2%, p ¼ 0.011), whereas tendenciesFig. 3. Representative photomicrographs of 5-hydroxymethylcytosine (5-hmC) immunoreac
CA3, and CA1-2 regions. (AeC) Non-demented control cases (ND) and (DeF) Alzheimer’s dise
ND controls in all 3 hippocampal subregions. Images were taken with a 40 objective. Scatowards statistical signiﬁcance were observed for neurons within
the CA3 (18.4%, p¼ 0.064) and the neurons in the CA1 (17.8%, p¼
0.083). No statistically signiﬁcant differences for glia cells in the
CA1 were found (Fig. 6).tivity (IR). High magniﬁcation representative photomicrographs of the hippocampal DG,
ase cases (AD). Note: A decrease of 5-hmC IR is observed in AD cases when compared to













Fig. 4. 5-mC and 5-hmC hippocampal ﬂuorescence intensities. Mean and standard
error of the mean of ﬂuorescence intensity measurements of 5-mC (A) and 5-hmC (B)
immunoreactivity (IR). Pooled data from the 3 hippocampal subregions of non-
demented control cases (ND; open bars) and Alzheimer’s disease cases (AD; ﬁlled
bars). The percentage of decrease in each analysis and the signiﬁcant effects (p < 0.05
in all cases) are indicated with an asterisk in each graph. Abbreviation: AU, arbitrary
units.
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Analysis of 5-hmC ﬂuorescence intensity in the twins discordant
for AD revealed a 31.4% reduction of 5-hmC IR in the CA1 of the























Fig. 5. Stratiﬁed hippocampal 5-mC ﬂuorescence intensities. Mean and standard error of th
Pooled data from the non-demented control cases (ND; open bars) and Alzheimer’s disease
The percentage of decrease in each analysis and the signiﬁcant effects (p < 0.05 in all casea reduction of 39.6% in the neurons and 20.7% in the glial cells of the
CA1 subregion of the AD twin compared to the ND twin (Fig. 7).
3.4. Correlation analyses
Linear correlation analyses revealed signiﬁcant negative corre-
lations between 5-mC IR and hippocampal amyloid plaque load
(rp ¼ 0.539, p ¼ 0.021), as well as 5-hmC IR and hippocampal
amyloid plaque load (rp ¼ 0.558, p ¼ 0.016). Similarly, a trend
toward statistical signiﬁcance for a negative correlation was
observed between hippocampal 5-mC IR and neuroﬁbrillary tangle
load (rp ¼ 0.461, p ¼ 0.054) (Fig. 8).
4. Discussion
Qualitative and quantitative assessment of the sections of the
human hippocampus revealed an AD-related decrease of both the
DNA methylation marker 5-mC and the DNA hydroxymethylation
marker 5-hmC. Moreover, similar patterns of decreased 5-hmC IR
were observed in the CA1 hippocampal subregion in the affected
twin of a monozygotic twin pair discordant for AD.
4.1. AD is associated with decreased hippocampal 5-mC IR
In the present study, we report that 5-mC IR, as a marker for
global DNA methylation, is decreased in the hippocampus of AD
patients when compared to ND controls. Pooled data from all cell
types and all regions also revealed a decrease in 5-hmC IR,
reﬂecting global DNA hydroxymethylation. Stratiﬁcation of the data
according to cell type and subregions reveals that the observed
differences are particularly pronounced in the CA1 neurons and
glial cells and in the glial cells residing in the CA3, whereas no
differences were observed in the DG.
The observed differences in 5-mC are in agreement with
previous reports of a global loss of methylation in the entorhinal
cortex of AD patients (Mastroeni et al., 2010) and can further be
linked to aberrant methylation patterns previously associated with
AD (Bakulski et al., 2012; Siegmund et al., 2007; Wang et al., 2008).
Although the exact reason of the observed methylation changes is
not yet clear, this might be related to AD-speciﬁc deﬁcits in the
nuclear transport of epigenetic molecules, such as Dnmt1, which is
responsible for maintenance of DNA methylation (Mastroeni et al.,
2013). This disturbed nucleocytoplasmic transport has been linked
with the downregulation of the Ras-related nuclear protein (RAN),
which plays an important role in the transport of molecules into







































e mean of ﬂuorescence intensity measurements of 5-mC immunoreactivity (IR) (AeC).
cases (AD; ﬁlled bars) are represented separately for the DG (A), CA3 (B), and CA1-2 (C).





























































Fig. 6. Stratiﬁed hippocampal 5-hmC ﬂuorescence intensities. Mean and standard error of the mean of ﬂuorescence intensity measurements of 5-hmC immunoreactivity (IR) (AeC).
Pooled data from the non-demented control cases (ND; open bars) and Alzheimer’s disease cases (AD; ﬁlled bars) are represented separately for the DG (A), CA3 (B), and CA1-2 (C).
Percentage of decrease in each analysis and the signiﬁcant effects (p < 0.05 in all cases) are indicated with an asterisk in each graph. Abbreviation: AU, arbitrary units.
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Besides DNA methylation marker 5-mC, which reﬂects a well-
known epigenetic modiﬁcation, the present study also addresses
5-hmC, which represents a recently described epigenetic modiﬁ-
cation. To our knowledge, this is the ﬁrst study to investigate
changes of 5-hmC in human AD. Pooled analyses showed a
decrease of 5-hmC IR in the hippocampus of AD patients
compared to ND controls, and stratiﬁed analyses showed that the
observed changes were more pronounced in the CA3 and the DG
regions. As with 5-mC IR, an AD-associated decrease was the main
effect, in both neurons and glial cells. Because 5-hmC is an
exclusive product of 5-mC, it could be speculated that the
observed changes in 5-hmC are closely associated with the
decrease of 5-mC. Interestingly, although age-associated increases
of hippocampal 5-hmC have been reported (Chouliaras et al., 2012;
Song et al., 2011) in normal aging, our recent work in transgenic
APPswe/PS1DE9 mice suggests a imbalance of hippocampal 5-mC
and 5-hmC in APPswe/Ps1DE9 when compared to that in wild-
type mice (Chouliaras et al., submitted), In parallel, another
study reported that a genetic variant of TET1, 1 of the enzymes that
catalyze DNA hydroxymethylation, is associated with an increased
risk of developing AD (Morgan et al., 2008). Such ﬁndings suggest
that 5-hmC and an altered methylation/hydroxymethylation







Fig. 7. Hippocampal 5-hmC ﬂuorescence intensities in the monozygotic twin pair discorda
rescence intensity measurements of 5-hmC immunoreactivity (IR) (A and B). Pooled data (A)
(ND; open bars) and Alzheimer’s disease case (twin) (AD; ﬁlled bars) are represented for the
each graph. Abbreviation: AU, arbitrary units.2012). The exact consequences of the observed changes of 5-hmC
are unknown, but as with 5-mC, could be associated with gene
expression alterations and cell-cycle reprogramming of cells in AD
(Blalock et al., 2004; Busser et al., 1998; Nagy et al., 1998),
considering that 5-hmC is known to play an important role in
regulating stem cell function (Haffner et al., 2011; Pastor et al.,
2011; Szulwach et al., 2011a).4.3. Twins
Similar to the comparison between AD cases and controls,
5-hmC IR was diminished in the hippocampus of the AD twin
compared to the ND sibling. Unfortunately, because of limitations
associated with the availability of brain materials from mono-
zygotic twins discordant for AD, wewere able to examine 5-hmC IR
only in the CA1 hippocampal subregion. Previous reports on the
same cases have already shown decrements of DNA methylation
and associated markers in the temporal neocortex of this twin pair
(Mastroeni et al., 2009). We now report that the hippocampal
5-hmC changes are comparable to the general cohort, with an
AD-associated decrease of hippocampal 5-hmC IR. Notably, the
occupation-related environmental exposures of the AD twin were
different from those of the ND twin, and this could be associated




























nt for Alzheimer’s disease cases (AD). Mean and standard error of the mean of ﬂuo-
and stratiﬁed data from neurons and glial cells (B) from the non-demented control case
CA1 hippocampal subregion. Percentages of decrease in each analysis are indicated in
Fig. 8. Correlation analysis between hippocampal 5-mC, 5-hmC immunoreactivity (IR) and amyloid plaque and neuroﬁbrillary tangle loads. Spearman’s correlation coefﬁcients and
p values are noted in the bottom of each graph.
L. Chouliaras et al. / Neurobiology of Aging 34 (2013) 2091e2099 20974.4. Negative correlations between hippocampal AD pathology and
DNA (hydroxy)methylation markers
There were negative correlations between hippocampal 5-mC
and 5-hmC IR and amyloid plaque pathology. Moreover, a trend
toward signiﬁcance pointed to a negative correlation between
5-mC IR and hippocampal neuroﬁbrillary tangle load. Such ﬁndings
suggest that AD pathology is associated with epigenetic changes.
However, it is not yet clear whether the observed epigenetic
changes are the cause or the consequence of AD pathology, and
future studies should therefore assess whether the observed
epigenetic changes precede AD pathology.
4.5. Conclusions and future directions
Future studies should identify the gene-speciﬁc epigenetic
changes that are associated with AD. Most of the techniques
developed to date require large amounts of input DNA, and whole-
tissue homogenates are mainly used for that purpose. However,
cell-type- and subregion-speciﬁc changes, and neuronal loss occur
in AD, whichmight alter the neurons/glia ratio when comparing AD
brains to controls (Blalock et al., 2011; Ginsberg et al., 2012; Liang
et al., 2008; Morrison and Hof, 2002; Torres-Munoz et al., 2004).
Thus, novel epigenetic approaches using cell-sorting or laser-
capture microdissected tissues and requiring less input material
should be further developed.
Interestingly, as epigenetic changes are responsive to environ-
mental stimuli, it should be examined whether brain-related
proﬁles correlate with peripheral proﬁles, and whether changes
of epigenetic markers in accessible tissue types may be used as
a biomarker for AD. Epigenetic mechanisms are inﬂuenced by
environmental exposures, and the data on discordant monozygotic
twins further supports this notion. Speciﬁc environmental expo-
sures that might be associated with AD, such as previous reports onmetal/lead exposure, related to the latent early-life associated
regulation (LEARn) model hypothesis, appear to be promising in
this aspect (Bihaqi and Zawia, 2012; Lahiri et al., 2009). Further-
more, speciﬁc geneeenvironment interactions should be investi-
gated, as it is known that the effect of certain environmental
exposures is highly dependent on individual genetic susceptibility
(Chouliaras et al., 2010b).
Future research needs also to investigate the exact genomic
localization and downstream effects of the observed AD-associated
epigenetic changes, such as the effects on histone modiﬁcations,
and gene and protein expression. Although it is not yet clear
whether epigenetic dysregulation is a cause or a consequence of the
disease, the fact that similar effects have also been observed in
transgenic APPswe/PS1DE9 mice (Chouliaras et al., submitted)
suggest that the observed DNA methylation and hydrox-
ymethylation changes might be triggered by the Ab pathology and
may be associated with disturbances of nuclear-cytoplasmic
transport of epigenetic molecules (Mastroeni et al., 2013). Given
the limitations of the current technologies and the limited avail-
ability of brain tissue, examination of peripheral blood in cohort
studies or animal studies could possibly answer these speciﬁc and
related questions. Furthermore, examination of correlations with
markers associated with the disease, such as cognitive decline,
synaptic deﬁcits, and neuronal loss, is of high importance (Coleman
and Yao, 2003; Rutten et al., 2005; Selkoe, 2002). Meanwhile, the
exact consequences of the observed epigenetic changes are
unknown; however, considering the role of epigenetic program-
ming in the development and differentiation of cells, it could be
speculated that the observed epigenetic changes induce gene
expression changes, the accumulation of which may result in
neuronal loss. As such, it will be crucial to clarify the involvement of
epigenetic changes in the pathophysiology of AD. The present
ﬁndings suggest that AD is associated with global changes of DNA
methylation and hydroxymethylation, and further show negative
L. Chouliaras et al. / Neurobiology of Aging 34 (2013) 2091e20992098correlations between these epigenetic markers and hippocampal
AD pathology.
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